表紙
市場調査レポート

抗体関連の各種提携契約:契約条件・合意内容

Global Antibody Partnering 2010-2016: Deal Trends, Players and Financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 234470
出版日 ページ情報 英文 829 Pages (including appendices)
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
抗体関連の各種提携契約:契約条件・合意内容 Global Antibody Partnering 2010-2016: Deal Trends, Players and Financials
出版日: 2016年03月01日 ページ情報: 英文 829 Pages (including appendices)
概要

当レポートでは、抗体関連の各種提携契約について調査分析し、近年における各種契約の動向、大規模契約および大手医薬品事業者による契約の概要、契約タイプ・開発ステージ・技術タイプ・治療/疾患科目別のディレクトリなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 抗体関連の各種契約動向

  • イントロダクション
  • 過去数年における抗体関連の提携
  • 大手製薬会社による契約活動
  • 大手バイオテク会社による契約活動
  • 抗体関連契約に積極的な上位10社
  • 抗体関連の提携:契約タイプ別
  • 抗体関連の提携:疾患区分別
  • 提携:抗体タイプ別
  • 平均的な契約条件
  • 抗体関連提携の分析

第3章 主要な抗体関連契約

  • イントロダクション
  • 主要契約:取引額別

第4章 大手医薬品企業による抗体関連契約

  • イントロダクション
  • 大手医薬品企業抗体関連契約の利用法
  • 大手製薬企業のプロファイル

第5章 大手バイオテク企業による抗体関連契約

第6章 契約ディレクトリ

  • イントロダクション
  • 企業別
  • 開発ステージ別
    • 創薬
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • 申請登録
    • 市販
  • 契約タイプ別
    • 資産購入
    • 権利譲
    • 大手医薬品企業のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同マーケティング
    • サービス契約
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売
    • 株式購入
    • 評価
    • 譲与
    • ジョイントベンチャー
    • ライセンシング
    • ローン
    • 製造
    • マーケティング
    • 材料転移
    • オプション
    • プロモーション
    • 研究
    • ロイヤルティファイナンシング
    • 和解関連
    • スピンアウト
    • サブライセンス
    • 供給
    • 技術移転
    • 契約解除
  • 治療科目別
    • 心血管
    • 中枢神経系
    • 皮膚科
    • 消化器
    • 血液
    • 免疫
    • 感染症
    • 筋骨格系疾患
    • 眼科
    • 呼吸器

第7章 抗体の種類別

第8章 抗体提携リソース

  • オンラインパートナリング
  • パートナリングイベント
  • 関連資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2113

The ‘Global Antibody Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,200 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

‘Global Antibody Partnering Terms and Agreements 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Antibody deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Antibody agreements with real life case studies
  • Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Antibody Partnering Terms and Agreements 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

‘Global Antibody Partnering Terms and Agreements 2010 to 2016’ includes:

  • Trends in Antibody dealmaking in the biopharma industry since 2010
  • Analysis of Antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Antibody deals
  • Access to over 1,200 Antibody online deal records
  • The leading Antibody deals by value since 2010
  • Most active Antibody dealmakers since 2010
  • The leading Antibody partnering resources

In ‘Global Antibody Partnering Terms and Agreements 2010 to 2016’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Antibody Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 1,200 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

  • 2.1. Introduction
  • 2.2. Antibody partnering over the years
  • 2.3. Most active antibody dealmakers
  • 2.4. Antibody partnering by deal type
  • 2.5. Antibody partnering by therapy area
  • 2.6. Deal terms for antibody partnering
    • 2.6.1. Antibody partnering headline values
    • 2.6.2. Antibody deal upfront payments
    • 2.6.3. Antibody deal milestone payments
    • 2.6.4. Antibody royalty rates

Chapter 3 - Leading antibody deals

  • 3.1. Introduction
  • 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibody dealmakers
  • 4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking
  • Appendices

Appendix 1 - Antibody deals by company A-Z

Appendix 2 - Antibody deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Antibody deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination

Appendix 4 - Antibody deals by therapy area

  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Psychiatry
  • Respiratory

Appendix 5 -Deal type definitions

  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Antibody partnering since 2010
  • Figure 3: Active antibody dealmaking activity- 2010 to 2016
  • Figure 4: Antibody partnering by deal type since 2010
  • Figure 5: Antibody partnering by disease type since 2010
  • Figure 6: Antibody deals with a headline value
  • Figure 7: Antibody deals with an upfront value
  • Figure 8: Antibody deals with a milestone value
  • Figure 9: Antibody deals with a royalty rate value
  • Figure 10: Top antibody deals by value since 2010
  • Figure 11: Most active antibody dealmakers 2010 to 2016
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top